WET AGE-RELATED MACULAR DEGENERATION
Clinical trials for WET AGE-RELATED MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new WET AGE-RELATED MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for WET AGE-RELATED MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
One-Shot gene therapy aims to free patients from monthly eye injections
Disease control Recruiting nowThis study is testing a one-time gene therapy called RGX-314 for people with wet age-related macular degeneration (wet AMD), a leading cause of vision loss. The goal is to see if this single treatment can help the eye make its own medicine to control the disease, potentially redu…
Matched conditions: WET AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 01, 2026 22:56 UTC
-
Gene test could match eye patients to best drug, save vision
Disease control Recruiting nowThis study aims to see if a person's genes can predict which of two common eye injections works better for treating wet age-related macular degeneration (AMD), a leading cause of vision loss. It will follow 630 patients for 3 years, comparing the standard drug ranibizumab with th…
Matched conditions: WET AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Parc de Salut Mar • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
One-Shot gene therapy could end decades of eye injections for millions
Disease control Recruiting nowThis study is testing a one-time gene therapy called RGX-314 for people with wet age-related macular degeneration (wet AMD), a leading cause of vision loss. The goal is to see if this single treatment can help control the disease long-term, potentially freeing patients from the b…
Matched conditions: WET AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC